While the Phase I trial was not primarily designed to assess the
efficacy of ATL1103, which will occur in larger and longer term clinical trials in patients, the results
achieved on these parameters in this trial in normal subjects indicate that ATL1103 demonstrated the
relevant pharmacological activity to support its further development as a potential treatment for
acromegaly and other growth hormone and IGF-I related disorders which include diabetic eye and
kidney complications and certain forms of cancer
atl1103 successfully progresses towards phase , page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
